Testing stimulant medications for PTSD
Part of Mental health clinical trials.
This study tests whether stimulant medications can help treat PTSD symptoms. Researchers want to see if these medications are safe and effective for people with PTSD.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be between 18 and 65 years old
- Have a body mass index (BMI) between 19 and 30
- Speak English fluently
- Not currently using stimulant medication
- No current moderate or severe substance use problems
- No recent suicide attempts or high risk of suicide
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of two medications (reboxetine and Ritalin) is more effective than dog-assisted therapy for reducing PTSD symptoms. Participation involves either taking the medications or attending dog therapy sessions.
This trial tests a study medicine that blocks the effects of cortisol (a stress hormone) to reduce PTSD symptoms in Veterans. It’s meant for people with ongoing PTSD symptoms and stable treatments, and it closely checks safety because the medicine can affect sleep, mood, and heart rhythm.
This Phase 2 trial tests whether therapy assisted by MDMA can reduce symptoms of moderate to severe post-traumatic stress disorder (PTSD) in eligible veterans. It includes supervised therapy sessions and extra study visits with video recording to track changes over time.
This trial tests if a single infusion of allopregnanolone (a natural brain chemical) can help people with PTSD reduce fear responses and improve memory processing. It may offer a new way to treat PTSD by targeting how the brain stores traumatic memories.
This trial tests if MDMA (a drug that can help with therapy) along with talk therapy can help military members with PTSD. It is designed for active duty, National Guard, or Reserve service members who have had PTSD for at least six months.
This Phase 2 study tests whether MDMA combined with therapy that uses exposure (gradual confronting of trauma memories) can reduce PTSD symptoms. It may help people who meet PTSD criteria, can follow strict safety rules, and can complete medicine-session monitoring.
Hear when a new PTSD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.